Today: 9 June 2026
Browse Category

NASDAQ:RVMD 7 January 2026 - 8 June 2026

AT&T Eyes June as Critical Month for Stock

AT&T Faces $4.5 Billion Cash Flow Hurdle as Stock Eyes Next Move

Revolution Medicines’ daraxonrasib doubled median survival to 13.2 months versus 6.7 for chemo in a 500-patient Phase 3 pancreatic cancer trial; risk of death cut by 60%. RVMD last quoted at $157.48 premarket, market cap $31.2B. FDA has allowed expanded access but drug remains unapproved. Company plans global regulatory filings; $1.9B cash at March 31 plus $2.1B from April financings. Q1 net loss widened to $453.8M.
1 June 2026
·
Revolution Medicines Stock Moves Premarket After Pancreatic Cancer Data

Revolution Medicines Stock Moves Premarket After Pancreatic Cancer Data

Revolution Medicines shares rose 1.9% premarket to $157.48 after Phase 3 trial data showed its experimental pill daraxonrasib nearly doubled median survival in pancreatic cancer to 13.2 months vs. 6.7 for chemo. The company, with no approved drugs or revenue, plans to file for FDA approval using a priority voucher. High-grade side effects were less common than chemo. Market cap stood at $31.2 billion.
1 June 2026
···
Revolution Medicines stock slips as Truist sticks to $99 target with Merck buyout talk in focus

Revolution Medicines stock slips as Truist sticks to $99 target with Merck buyout talk in focus

Revolution Medicines shares fell 1.8% to $116.51 in early Monday trading, retreating from last week’s highs after reports of ongoing Merck acquisition talks valuing the company at up to $32 billion. Truist maintained its Buy rating but kept its price target at $99, below the current price. Investors await the company’s presentation at the J.P. Morgan Healthcare Conference later Monday.
12 January 2026
··
Merck (MRK) stock week ahead: $30 billion Revolution talks and JPMorgan catalysts to watch

Merck (MRK) stock week ahead: $30 billion Revolution talks and JPMorgan catalysts to watch

Merck shares fell 0.4% to $110.53 Friday as reports surfaced of talks to buy Revolution Medicines in a deal valued at $28 billion to $32 billion. Revolution shares jumped 10.7% on the speculation. The Wall Street Journal and Financial Times said the deal would be among the largest pre-commercial biotech acquisitions. Investors await updates at the JPMorgan Healthcare Conference on Monday.
11 January 2026
···
Revolution Medicines stock in focus as Merck buyout talk hangs over RVMD into JPMorgan week

Revolution Medicines stock in focus as Merck buyout talk hangs over RVMD into JPMorgan week

Revolution Medicines shares jumped 10.7% to $118.64 Friday amid reports Merck is in talks to acquire the company for up to $32 billion, according to the Financial Times. Trading volume hit 20.8 million shares. AbbVie denied it was in discussions after an earlier report, sending Revolution’s stock down 11.5% after hours. The FDA granted Breakthrough Therapy status to Revolution’s lung cancer drug candidate.
11 January 2026
··
Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK

Merck stock: $32 billion Revolution Medicines talks and vaccine-policy shift set up a busy week for MRK

Merck shares fell 0.4% to $110.53 Friday after reports it is in talks to acquire Revolution Medicines for $28–32 billion. Revolution shares jumped in after-hours trading. The Financial Times said negotiations are ongoing, with no final deal yet. Investors are watching Merck’s appearance at the J.P. Morgan Healthcare Conference on Jan. 12.
10 January 2026
··
Revolution Medicines stock jumps on Merck buyout buzz and an FDA breakthrough tag — what to watch Monday

Revolution Medicines stock jumps on Merck buyout buzz and an FDA breakthrough tag — what to watch Monday

Revolution Medicines shares surged 10.7% to $118.64 Friday after reports that Merck is in talks for a $28–32 billion takeover. The FDA granted Breakthrough Therapy status to its lung cancer drug zoldonrasib. Insider filings show the CFO and COO sold shares earlier in the week under pre-arranged plans. Revolution denied rumors of a separate AbbVie bid.
10 January 2026
·
Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

Merck stock dips after $32 billion Revolution Medicines talks report, with Gardasil and Keytruda in focus

Merck shares fell 0.4% to $110.53 after reports it is in talks to acquire Revolution Medicines for up to $32 billion. The company faces new scrutiny over its Gardasil and RotaTeq vaccines after U.S. policy changes, with analysts estimating a $2 billion annual revenue impact. Wolfe Research upgraded Merck, citing progress on a subcutaneous version of Keytruda.
10 January 2026
····
Merck buyout chatter jolts Revolution Medicines (RVMD) stock after FDA breakthrough nod

Merck buyout chatter jolts Revolution Medicines (RVMD) stock after FDA breakthrough nod

Revolution Medicines shares surged 10.7% to $118.64 in after-hours trading Friday after the Financial Times reported Merck is in advanced talks to acquire the company for $28 billion to $32 billion. The move follows the FDA granting Breakthrough Therapy designation to Revolution’s zoldonrasib for KRAS G12D-mutated lung cancer. Investors await Revolution’s Jan. 12 conference appearance for updates.
9 January 2026
··
Revolution Medicines stock rises as Merck buyout talks swirl; FDA designation adds another spark

Revolution Medicines stock rises as Merck buyout talks swirl; FDA designation adds another spark

Revolution Medicines shares rose 4.3% to $112.00 Friday after reports that Merck is in talks to buy the company for up to $32 billion. The FDA granted Breakthrough Therapy designation to Revolution’s KRAS-targeting lung cancer drug this week. AbbVie denied involvement in any deal. Revolution declined to comment on the takeover speculation.
9 January 2026
··
Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck (MRK) stock today: $32 billion Revolution talks and CDC vaccine shift put Feb. 3 in play

Merck shares rose 0.4% to $111.41 Friday after a report said it is in talks to buy Revolution Medicines for $28–32 billion. Revolution shares jumped 16% in extended trading. Merck just completed a $221.50-per-share tender offer for Cidara Therapeutics and said the deal will raise 2026 R&D expense by $9 billion. Analysts warned U.S. vaccine policy changes could cut Merck revenue by $2 billion annually.
9 January 2026
···
AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders

AbbVie stock drops after Revolution deal denial, $1.3 billion charge spooks traders

AbbVie shares fell 3.7% to $224.84 Thursday after the company denied takeover talks with Revolution Medicines and flagged a $1.3 billion fourth-quarter charge tied to R&D and milestone payments. AbbVie trimmed its 2025 profit forecast, setting adjusted earnings at $9.90 to $9.94 per share. Revolution Medicines dropped 5.5%. Wolfe Research downgraded AbbVie, citing limited upside.
8 January 2026
··
Revolution Medicines (RVMD) stock slips in premarket as AbbVie denies takeover talks, deal buzz lingers

Revolution Medicines (RVMD) stock slips in premarket as AbbVie denies takeover talks, deal buzz lingers

Revolution Medicines shares dropped 9.8% to $92.60 premarket after AbbVie denied takeover talks, erasing gains from a rumor-fueled surge. AbbVie’s denial followed a Wall Street Journal report of advanced deal discussions. A Form 144 filing showed officer Jack Lee Anders notified a proposed sale of 10,000 shares. CEO Mark Goldsmith is scheduled to present at the J.P. Morgan Healthcare Conference on Jan. 12.
8 January 2026
AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

AbbVie stock drops before the bell after Revolution Medicines deal talk gets swatted down

AbbVie shares fell 1.6% to $229.64 premarket after the company denied talks to acquire Revolution Medicines and cut its 2025 profit forecast. Revolution stock dropped 11.5% following AbbVie’s statement. AbbVie now expects 2025 adjusted EPS of $9.90 to $9.94, down from its previous outlook, citing a $1.3 billion acquired IPR&D charge. Earnings are due Feb. 4.
8 January 2026
···
AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

AbbVie stock slips after hours after denying Revolution Medicines talks, trims 2025 profit view

AbbVie shares fell 1% to $231.11 in after-hours trading after the company denied reports of takeover talks with Revolution Medicines. A new SEC filing flagged a $1.3 billion fourth-quarter charge, prompting AbbVie to cut its 2025 adjusted earnings forecast to $9.90–$9.94 per share from $10.61–$10.65. Revolution shares dropped 11.5% late.
8 January 2026
····

Stock Market Today

  • Q1 Cybersecurity Earnings: Varonis Systems and Palo Alto Networks Lead Growth
    June 8, 2026, 6:23 PM EDT. Cybersecurity stocks showed resilience in Q1, with revenues surpassing analysts' estimates by 1.6% on average. Varonis Systems (NASDAQ:VRNS) led the pack, reporting revenues of $173.1 million, a 26.9% year-on-year increase, beating forecasts by 4.6%. CEO Yaki Faitelson highlighted Varonis' strong growth in SaaS Annual Recurring Revenue (ARR) and its positioning to capitalize on the growing AI security market. Palo Alto Networks (NASDAQ:PANW) also posted robust results, with Q1 revenues hitting $3 billion, up 31.1%, outperforming estimates by 2%. The group's average share price has risen 6.1% since earnings, reflecting market confidence amid increasing cybersecurity demand driven by cloud adoption and evolving threats.

Latest articles

OpenAI IPO filing puts AI rally at center stage for Wall Street

OpenAI IPO filing puts AI rally at center stage for Wall Street

9 June 2026
OpenAI has confidentially filed for a possible IPO, but investors won’t see key financials—including revenue quality, cash burn, and compute costs—until the S-1 goes public; with $2 billion monthly revenue and a recent $852 billion valuation, the filing signals a pivotal shift as AI giants race for public capital amid rising infrastructure costs and growing competition from Anthropic.
Wall Street Volatility Index Jumps as Chip Stocks Swing

Wall Street Volatility Index Jumps as Chip Stocks Swing

9 June 2026
The VIX plunged 12% to 18.92 as chip stocks rebounded sharply, with the Philadelphia Semiconductor Index jumping 5.6% and Intel soaring 11.2% after a major Google order, clawing back part of Friday’s $1.3 trillion rout; investors remain cautious ahead of key inflation data, interest rate decisions, and Middle East risks.
UBS Puts $850 Target on Cummins as AI Data Center Wave Fuels Shares

UBS Puts $850 Target on Cummins as AI Data Center Wave Fuels Shares

9 June 2026
UBS upgraded Cummins to Buy and hiked its price target to $850 from $565, citing surging data-center backup power demand and a stronger North American truck cycle; Cummins shares jumped 3.3% to $672.68 as UBS projected 2028 EPS of $41.25, topping consensus, and flagged double-digit Power business growth and raised long-term targets as key drivers.
UiPath Stock Slips Near $11 as Wall Street Questions the AI Automation Bounce

UiPath Stock Slips Near $11 as Wall Street Questions the AI Automation Bounce

8 June 2026
UiPath shares dipped 0.7% to $11.17 despite a strong quarter and raised outlook, as investors focused on slow annual recurring revenue growth and analyst caution, with Morgan Stanley cutting its price target and BofA maintaining Underperform, citing the need for clearer evidence that AI-driven automation can accelerate durable contract revenue.
IREN Shares Rally After Bitcoin Rebound and $4.4 Billion AI Data Center Move

IREN Shares Rally After Bitcoin Rebound and $4.4 Billion AI Data Center Move

8 June 2026
IREN surged 9% to $59.19 as investors returned to crypto and AI infrastructure stocks after last week’s selloff, driven by a $3.65 billion investment-grade GPU financing to support its Microsoft AI cloud contract and news of a planned 800MW data-center in Australia, but future gains hinge on execution, contract delivery, and bitcoin price stability.
Go toTop